Mostrar el registro sencillo del ítem
dc.contributor.author | Domínguez Rodríguez, Alberto | |
dc.contributor.author | Abreu González, Pedro | |
dc.contributor.author | Torre Hernández, Jose M. de la | |
dc.contributor.author | González González, Julia | |
dc.contributor.author | García Camarero, Tamara | |
dc.contributor.author | Consuegra Sánchez, Luciano | |
dc.contributor.author | García-Saiz, María del Mar | |
dc.contributor.author | Aldea-Perona, Ana | |
dc.contributor.author | Virgos Aller, Tirso | |
dc.contributor.author | Azpeitia, Agueda | |
dc.contributor.author | Reiter, Russel J. | |
dc.date.accessioned | 2017-12-07T17:13:32Z | |
dc.date.available | 2017-12-07T17:13:32Z | |
dc.date.issued | 2017 | |
dc.identifier.citation | Dominguez‐Rodriguez, A., Abreu‐Gonzalez, P., Torre‐Hernandez, J. M., Gonzalez‐Gonzalez, J., Garcia‐Camarero, T., Consuegra‐Sanchez, L., ... & Reiter, R. J. (2017). Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST‐elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial. Journal of Pineal Research, 62(1). | spa |
dc.identifier.issn | 0742-3098 | |
dc.identifier.uri | http://hdl.handle.net/11268/6837 | |
dc.description.abstract | The MARIA randomized trial evaluated the efficacy and safety of melatonin for the reduction of reperfusion injury in patients undergoing revascularization for ST-elevation myocardial infarction (STEMI). This was a prespecified interim analysis. A total of 146 patients presenting with STEMI within 6 hours of chest pain onset were randomized to receive intravenous and intracoronary melatonin (n=73) or placebo (n=73) during primary percutaneous coronary intervention (PPCI). Primary endpoint was myocardial infarct size as assessed by magnetic resonance imaging (MRI) at 6 ± 2 days. Secondary endpoints were changes in left ventricular volumes and ejection fraction (LVEF) at 130 ± 10 days post-PPCI and adverse events during the first year. No significant differences in baseline characteristics were observed between groups. MRI was performed in 108 patients (86.4%). Myocardial infarct size by MRI evaluated 6 ± 2 days post-PPCI, did not differ between melatonin and placebo groups (P=.63). Infarct size assessed by MRI at 130 ± 10 days post-PPCI, performed in 91 patients (72.8%), did not show statistically significant differences between groups (P=.27). The recovery of LVEF from 6 ± 2 to 130 ± 10 days post-PPCI was greater in the placebo group (60.0 ± 10.4% vs 53.1 ± 12.5%, P=.008). Both left ventricular end-diastolic and end-systolic volumes were lower in the placebo group (P=.01). The incidence of adverse events at 1 year was comparable in both groups (P=.150). Thus, in a nonrestricted STEMI population, intravenous and intracoronary melatonin was not associated with a reduction in infarct size and has an unfavourable effect on the ventricular volumes and LVEF evolution. Likewise, there is lack of toxicity of melatonin with the doses used. | spa |
dc.description.sponsorship | Sin financiación | spa |
dc.language.iso | eng | spa |
dc.title | Effect of intravenous and intracoronary melatonin as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the Melatonin Adjunct in the acute myocaRdial Infarction treated with Angioplasty trial | spa |
dc.type | article | spa |
dc.description.impact | 11.613 JCR (2017) Q1, 6/143 Endocrinology and Metabolism, 11/261 Neurosciences, 3/83 Physiology | spa |
dc.identifier.doi | 10.1111/jpi.12374 | |
dc.rights.accessRights | closedAccess | spa |
dc.subject.uem | Cardiología | spa |
dc.subject.unesco | Enfermedad cardiovascular | spa |
dc.description.filiation | UEC | spa |
dc.peerreviewed | Si | spa |
Ficheros | Tamaño | Formato | Ver |
---|---|---|---|
No hay ficheros asociados a este ítem. |